Volume 28

  • No. 6 June 2022

    Neutralizing Omicron sublineages

    In this issue, Bruel et al. demonstrate substantial differences in the sensitivity of the SARS-CoV-2 Delta variant and Omicron sublineages BA.1 and BA.2 to neutralization by nine therapeutic monoclonal antibodies. The cover combines an image of SARS-CoV-2-infected cells fusing with neighboring cells to form syncytia with a view of Earth, reflective of the ongoing global impact of the pandemic.

    See Bruel et al.

  • No. 5 May 2022

    Polygenic risk scores in transplantation

    Shaked et al. applied a polygenic risk score for type 2 diabetes to liver and kidney transplant donors and recipients with the aim of identifying genetic associations with the development of post-transplantation diabetes mellitus. The cover is illustrative of genetic puzzle pieces in both the donor and the recipient, which can be leveraged to inform and develop personalized treatment strategies and to optimize donor–recipient matching.

    See Shaked et al.

  • No. 4 April 2022

    The future of cancer research

    This special Focus issue presents an overview of the most promising developments in cancer research, with an eye toward delivering research and care that is innovative, equitable, sustainable and patient-focused. The cover presents an artistic rendition of the study by Seliger and colleagues, in this issue, showing an increased risk of death by suicide in patients with cancer and underscoring the need for comprehensive psycho-oncological therapy during routine clinical practice to improve the quality of life of such patients.

    See Focus

  • No. 3 March 2022

    Health in the Amazon

    Local communities protect the Amazon rainforest from illegal logging and mining, but this is threatened by a lack of local healthcare. Journalist Sofia Moutinho traveled with a medical team who delivered vaccines for COVID-19 and other supplies during a monthlong boat trip along the Amazon River.

    See News Feature

  • No. 2 February 2022

    CD19 CAR T cells in follicular lymphoma

    Fowler et. al report their primary analysis of the ELARA phase 2 trial of tisagenlecleucel, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, that showed a robust response and manageable safety profile in heavily pre-treated patients with relapsed/refractory follicular lymphoma. Captured in a moment of suspense, the illustrated cover casts a retro space-age mood over the scene as a tisagenlecleucel CAR T cell recognizes and targets a CD19-expressing follicular lymphoma within the tumor microenvironment, highlighting the selective and specific mechanism of this novel cellular therapy.

    See Fowler et al.

  • No. 1 January 2022

    Targeting lipoprotein(a) with siRNA

    Lipoprotein ‘a’ [Lp(a)] is a causal genetic risk factor for atherosclerotic cardiovascular disease. Koren et al. describe the early development of olpasiran, a hepatocyte-targeted small interfering RNA that potently and durably reduces plasma Lp(a) concentrations in humans. Lp(a) particles are composed of a lipid-rich core (yellow sphere) associated with a protein complex that consists of apolipoprotein(a) (apo(a), shown as a coiled structure with conserved kringle repeats in different colors) covalently bound to apolipoprotein B-100. The number of apo(a) kringle repeats is genetically defined, varies widely between individuals, and determines plasma concentrations of Lp(a).

    See Koren et al.